Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
NASDAQ:CDT

CDT Equity 8/14/2025 Earnings Report

CDT Equity logo
$1.68 +0.14 (+9.09%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.65 -0.03 (-1.79%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

CDT Equity EPS Results

Actual EPS
-$5.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CDT Equity Announcement Details

Quarter
Date
8/14/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CDT Equity Earnings Headlines

Conduit to Change Name to CDT Equity Inc.
August 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/conduit-change-name-cdt-equity-123000903.html
CDT Conduit Pharmaceuticals Inc. - Seeking Alpha
July 11, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/CDT
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
August 24 at 2:00 AM  |  Porter & Company (Ad)
Conduit Pharmaceuticals Files First Patent for AZD5658 and New Combination Patents for AZD1656 and AZD5658 in Collaboration with Sarborg Limited - Nasdaq
July 9, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/conduit-pharmaceuticals-files-first-patent-azd5658-and-new-combination-patents-azd1656-and
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111018/0/en/conduit-pharmaceuticals-files-new-patents-following-ai-driven-combination-discoveries.html
CDT - Conduit Pharmaceuticals Inc Dividends - Morningstar
July 4, 2025  |  morningstar.comM
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View CDT Equity Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles